Clinical trials: Metastatic Castration-Resistant Prostate Adenocarcinoma
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies the safety, tolerability and how well durvalumab and tremelimumab work in treating participants with castration-resistant prostate cancer who have not received chemotherapy (chemotherapy naïve) and has…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT03204812
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT02099864
- Testing
- Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- OHSU Knight Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
This phase II trial studies how well erdafitinib in combination with abiraterone acetate or enzalutamide works in treating patients with double negative prostate cancer.
- Conditions
- Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03999515
- Testing
- Abiraterone Acetate, Enzalutamide, Erdafitinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Washington
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
This phase II trials studies the side effects and how well ESK981 works in treating patients with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression
- Trial name
- NCT03456804
- Testing
- ESK981
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Prostate Adenocarcinoma, Castration-resistant Prostate Cancer
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
This research study is examining whether Neratinib has any activity in participants with prostate cancer that has spread and is no longer responding to hormonal treatment.
- Conditions
- Metastatic Prostate Adenocarcinoma, Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Cancer Metastatic
- Trial name
- NCT04781374
- Testing
- Neratinib
- Where
- 3 sites in United States
- Sponsor
- Beth Israel Deaconess Medical Center
Metastatic Castration-Resistant Prostate Adenocarcinoma
First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer
CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part, first-in-human study to assess the safety and tolerability of CCW702 administered subcutaneously to patients with metastatic, castration…
- Trial name
- NCT04077021
- Testing
- CCW702
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Calibr, a division of Scripps Research
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
This phase II trial studies how well pembrolizumab and HER2Bi-armed activated T cells work in treating patients with castration resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression
- Trial name
- NCT03406858
- Testing
- HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this phase II, single-arm, open-label, three center study is to evaluate the efficacy, safety, and tolerability of sEphB4-HSA in patients with mCRPC (metastatic castration-resistant prostate cancer).
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT04033432
- Testing
- Recombinant EphB4-HSA Fusion Protein
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
This partially randomized phase I/II trial studies cabazitaxel with or without carboplatin in treating patients with previously treated prostate cancer that has spread to other areas of the body and does not respond to treatment…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma
- Trial name
- NCT01505868
- Testing
- Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 170 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Castration-resistant Prostate Cancer, Adenocarcinoma of the Prostate
Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
The objective of this clinical study is to evaluate the effectiveness and safety of selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy - among patients diagnosed with metastatic…
- Trial name
- NCT04586543
- Testing
- Selegiline, Docetaxel
- Where
- Hungary
- Volunteers
- 110 people
- Sponsor
- László Mangel
Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC)
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in…
- Conditions
- Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT03811652
- Testing
- MEDI7247
- Where
- 3 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- MedImmune LLC
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies selinexor in treating patients with prostate cancer that has spread to other parts of the body (metastatic), keeps growing even when the amount of testosterone in the body is reduced to very low levels…
- Conditions
- Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT02215161
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
This phase I trial studies the side effects and best dose of niclosamide when given together with enzalutamide in treating patients with castration resistant prostate cancer that has spread from the primary site to other places…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT02532114
- Testing
- Enzalutamide, Laboratory Biomarker Analysis, Niclosamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington